glp-1 drug news Americans are taking weight-loss drugs in record numbers GLP-1 Drugs May Expand Beyond

Purpose of Review This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinsons disease (PD), focusing on body weight regulation and neuroprotection

But for complex drugs like this, quality control is still improving

The Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market worth USD 2.91 billion in 2026 is growing at a CAGR of 8.24% to reach USD 4.33 billion by 2031

Some people covered by Medicare or Medicare Advantage now qualify for GLP-1 weight loss drugs at a lower price - $50 a month

Clinician-focused drug-drug interaction reference for GLP-1 receptor agonists including semaglutide, liraglutide, dulaglutide, tirzepatide, and exenatide